Cargando…
Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer
SIMPLE SUMMARY: Stage IV (metastatic) prostate cancer remains an incurable disease despite many treatment advances in recent years. Approximately a quarter of men with advanced prostate cancer have alterations in DNA repair pathways, namely, homologous recombination repair (HRR). Poly(ADP-ribose) po...
Autores principales: | Inderjeeth, Andrisha-Jade, Topp, Monique, Sanij, Elaine, Castro, Elena, Sandhu, Shahneen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9736565/ https://www.ncbi.nlm.nih.gov/pubmed/36497408 http://dx.doi.org/10.3390/cancers14235922 |
Ejemplares similares
-
Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
por: Jannetti, Stephen A., et al.
Publicado: (2020) -
The Inhibition and Treatment of Breast Cancer with Poly (ADP-ribose) Polymerase (PARP-1) Inhibitors
por: De Soto, Joseph A., et al.
Publicado: (2006) -
Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
por: Faraoni, Isabella, et al.
Publicado: (2018) -
Novel radionuclide therapy combinations in prostate cancer
por: Inderjeeth, Andrisha–Jade, et al.
Publicado: (2023) -
Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) – Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy
por: Harrision, Daniel, et al.
Publicado: (2020)